In this podcast interview, ASCO experts talk about new research on patient participation in clinical trials.

Cancer.Net Associate Editors explain research presented at the 2019 ASCO Annual Meeting, including new research in colon cancer, gastric cancer, pancreatic cancer, and leukemia.

In this podcast, Cancer.Net Associate Editors discuss new research from the 2019 ASCO Annual Meeting and explain what it means for people with cancer.

Cancer.Net Associate Editors share new insights from research presented at the 2019 ASCO Annual Meeting.

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.

2018-2019 ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, describes how visiting and talking with people with cancer and providers across the United States highlights the importance of access to cancer care.

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.

Watch a video featuring 2018–2019 ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, discussing the theme for the 2019 ASCO Annual Meeting.

Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.